4-{hydroxy[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl }benzoic acid | 397327-90-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-{hydroxy[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl }benzoic acid
• 英文别名: 4-[[1-(Benzenesulfonyl)pyrrol-2-yl]-hydroxymethyl]benzoic acid
• CAS: 397327-90-1
• 化学式: C₁₈H₁₅NO₅S
• 分子量: 357.387
• InChiKey: BFTHKSYBZPFKKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• FIBROSIS INHIBITOR
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1479384A1

  公开（公告）日：2004-11-24

  Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

  药物作为器官或组织的纤维化抑制剂而有用，包括具有以下式（I）的化合物： 其中环Z是可选择取代的吡咯环等；W2是-CO-，-SO2-，可选择取代的C1-C4烷基等；Ar2是可选择取代的芳基等；W1和Ar1表示如下（1）和（2）： （1）W1是可选择取代的C1-C4烷基等；Ar1是可选择取代的具有1至4个氮原子作为环形成原子的双环杂芳基： （2）W1是可选择取代的C2-C5烷基，可选择取代的C2-C5烯基等；以及 Ar1是芳基或单环杂芳基，其在相对于W1的结合位置的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐。
• Pyrrole derivatives
  申请人：——

  公开号：US20030181496A1

  公开（公告）日：2003-09-25

  Pyrrole derivatives represented by the following formula: 1 wherein Ring Z is an optionally substituted pyrrole ring, etc.; W 2 is —CO—, —SO 2 —, an optionally substituted C 1 -C 4 alkylene, etc.; Ar 2 is an optionally substituted aryl, etc.; W 2 and Ar 1 mean the following (1) and (2): (1) W 1 is an optionally substituted C 1 -C 4 alkylene, etc.; Ar 1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W 1 is an optionally substituted C 2 -C 5 alkylene, an optionally substituted C 2 -C 5 alkenylene, etc.; and Ar 1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W 1 , or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

  以下是用中文翻译的结果： 由以下公式表示的吡咯衍生物： 其中环Z是可选择取代的吡咯环等；W 2 是—CO—，—SO 2 —，可选择取代的C 1 -C 4 烷基等；Ar 2 是可选择取代的芳基等；W 2 和Ar 1 表示如下（1）和（2）： （1）W 1 是可选择取代的C 1 -C 4 烷基等；Ar 1 是具有1至4个氮原子作为环形成原子的可选择取代的双环杂芳基： （2）W 1 是可选择取代的C 2 -C 5 烷基，可选择取代的C 2 -C 5 烯基等；Ar 1 是芳基或单环杂芳基，其在与W 1 的结合位置相对应的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐 这些化合物可用作器官或组织的纤维化抑制剂等药物。
• Fibrosis inhibitor
  申请人：Tokunaga Teruhisa

  公开号：US20050227978A1

  公开（公告）日：2005-10-13

  Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W 2 is —CO—, —SO 2 —, optionally substituted C 1 -C 4 alkylene, etc.; Ar 2 is optionally substituted aryl, etc.; W 1 and Ar 1 mean the following (1) and (2): (1) W 1 is optionally substituted C 1 -C 4 alkylene, etc.; Ar 1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W 1 is optionally substituted C 2 -C 5 alkylene, optionally substituted C 2 -C 5 alkenylene, etc.; and Ar 1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W 1 , or a pharmaceutically acceptable salt thereof.

  药物作为纤维化抑制剂对器官或组织有用，包括式(I)的化合物，其中环Z是可选取代的吡咯环等; W2是- CO-，-SO2-，可选取代的C1-C4烷基等; Ar2是可选取代的芳基等; W1和Ar1表示以下(1)和(2):(1)W1是可选取代的C1-C4烷基等; Ar1是具有1至4个氮原子作为环形成原子的可选取代的双环杂环芳基;(2)W1是可选取代的C2-C5烷基，可选取代的C2-C5烯基等; Ar1是芳基或单环杂环芳基，其在与W1的结合位置相对的邻位或间位上被羧基，烷氧基羰基等取代，或其药学上可接受的盐。
• PYRROLE DERIVATIVES
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1310485A1

  公开（公告）日：2003-05-14

  Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

  下式所代表的吡咯衍生物： 其中环 Z 是任选取代的吡咯环等；W2 是-CO-、-SO2-、任选取代的 C1-C4 亚烷基等；Ar2 是任选取代的芳基等；W2 和 Ar1 的含义如下(1)和(2)： (1) W1 是任选取代的 C1-C4 亚烷基等；Ar1 是任选取代的具有 1 至 4 个氮原子作为成环原子的双环杂芳基： (2) W1 是任选取代的 C2-C5 亚烷基、任选取代的 C2-C5 烯基等；Ar1 是芳基或单环杂芳基，这些芳基或单环杂芳基相对于 W1 的结合位置，在其正位或偏位被羧基、烷氧羰基等取代、 或其药学上可接受的盐 这些化合物可用作药物，如器官或组织纤维化抑制剂。
• US6759429B2
  申请人：——

  公开号：US6759429B2

  公开（公告）日：2004-07-06